Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES. (6th October 2021)

• Record Type: Journal Article
• Authors: Yeoh, Su E.; Dewan, Pooja; Serenelli, Matteo; Ferreira, João Pedro; Pitt, Bertram; Swedberg, Karl; van Veldhuisen, Dirk J.; Zannad, Faiez; Jhund, Pardeep S.; McMurray, John J.V.
• Is Part Of: European journal of heart failure. Volume 24:Number 3(2022)
• Page Start: 529
• Page End: 538
• Publication Date: 2021-10-06
• Subjects: Heart failure -- Mineralocorticoid receptor antagonists -- Chronic obstructive pulmonary disease; Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1002/ejhf.2350
• Languages: English
• ISSNs: 1388-9842

Abstract

Abstract: Aims: Heart failure with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) individually cause significant morbidity and mortality. Their coexistence is associated with even worse outcomes, partly due to suboptimal heart failure therapy, especially underutilisation of beta‐blockers. Our aim was to investigate outcomes in HFrEF patients with and without COPD, and the effects of mineralocorticoid receptor antagonists (MRAs) on outcomes. Methods and results: We studied the effect of MRA therapy in a post‐hoc pooled analysis of 4397 HFrEF patients in the RALES and EMPHASIS‐HF trials. The primary endpoint was the composite of heart failure hospitalisation or cardiovascular death. A total of 625 (14.2%) of the 4397 patients had COPD. Patients with COPD were older, more often male, and smokers, but less frequently treated with a beta‐blocker. In patients with COPD, event rates (per 100 person‐years) for the primary endpoint and for all‐cause mortality were 25.2 (95% confidence interval 22.1–28.7) and 17.2 (14.9–19.9), respectively, compared with 19.9 (18.8–21.1) and 12.8 (12.0–13.7) in participants without COPD. The risks of all‐cause hospitalisation and sudden death were also higher in patients with COPD. The benefit of MRA, compared with placebo, was consistent in patients with or without COPD for all outcomes, e.g. hazard ratio for the primary outcome 0.66 (0.50–0.85) for COPD and 0.65 (0.58–0.73) for no COPD (interaction p = 0.93). MRA‐induced hyperkalaemia was less frequent in patients with COPD. Conclusions: In RALES and EMPHASIS‐HF, one‐in‐seven patients with HFrEF had coexisting COPD. HFrEF patients with COPD had worse outcomes than those without. The benefits of MRAs were consistent, regardless of COPD status.